Pivotal Therapeutics Inc., Toronto, Ontario, Canada, has filed five provisional patent applications with the U.S. Patent and Trademark Office. The patent applications represent the initial filings contemplated by Pivotal Therapeutics in the development of a comprehensive patent portfolio to protect its lead product Vascazen, a prescription-grade omega 3 formula. Vascazen’s unique EPA to DHA ratio contains fish oils produced exclusively for Pivotal Therapeutics by a unique patented manufacturing process, which ensures these oils are of the highest purity.